Results 211 to 220 of about 39,211 (299)

CYP2C19 Genotyping to Guide Clopidogrel Prescribing for Neurovascular Indications: A Survey of Institutional Approaches

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 937-942, October 2026.
Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is commonly used for secondary prevention following acute ischemic stroke (AIS) and neurointerventional procedures. However, the efficacy of clopidogrel is reduced in carriers of CYP2C19 no‐function alleles.
Rachael M. Stone, Glenda Hoffecker, April Schultz, Brittney H. Davis, Salma A. Bargal, Amber L. Beitelshees, Nihal El Rouby, Madeline Norris, Kevin J. Rodriguez, Nita Limdi, Larisa H. Cavallari, Craig R. Lee   +11 more
wiley   +1 more source

In defence of the drug, two hearts, one profession: Reintegrating medicines expertise and patient-centred care in pharmacy's professional identity. [PDF]

Explor Res Clin Soc Pharm
Davies NM.
europepmc   +1 more source

Fecal Microbiota Transplantation and Microbiota‐Based Therapeutics in Allogeneic Hematopoietic Stem Cell Transplantation: Current Evidence and Future Directions

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 871-889, October 2026.
The intestinal microbiome is a key regulator of immune homeostasis, metabolism, and epithelial barrier integrity. In patients with malignant hematological diseases, particularly those undergoing hematopoietic stem cell transplantation, microbiome perturbations by reduced diversity, pathobiont expansion, and loss of beneficial metabolites are common as ...
Bálint Gergely Szabó, Dorina Korózs, Michal Bator, Krisztina Jeszenszky, Viktor Lakatos, László Gopcsa, Péter Reményi, János Sinkó   +7 more
wiley   +1 more source

Clinical Function Assignment of NAT2 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1101-1110, October 2026.
NAT2 encodes arylamine N‐acetyltransferase 2, a key enzyme in the phase II metabolism of arylamines and arylhydrazines. NAT2 is highly polymorphic, resulting in variable distributions of rapid and poor metabolizers across global populations. Here, we detail the process undertaken by the Clinical Pharmacogenetics Implementation Consortium (CPIC) NAT2 ...
Bailey M. Tibben, David W. Hein, Michelle Whirl‐Carrillo, Andrea Gaedigk, Michael T. Eadon, Rodney F. Minchin, Sotiria Boukouvala, Adalberto Rezende Santos, Roseann S. Donnelly, José A. G. Agúndez, Kelly E. Caudle   +10 more
wiley   +1 more source

Pharmacogenomics and Opioid Efficacy in Sickle Cell Disease: Is the Field Ready for Precision Prescribing? [PDF]

J Pers Med
Jaja C, Sop DM, Campbell A, Smith WR.
europepmc   +1 more source

Operationalizing Precision Medicine in Drug Development: Predictive Biomarkers, Companion Diagnostics, and Regulatory Pathways

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 914-929, October 2026.
Precision medicine offers the opportunity to improve the benefit–risk profile of new therapies by prospectively identifying patients most likely to respond or least likely to experience harm; however, its systematic integration into drug development remains inconsistent outside oncology.
Ingrid Holst‐Laubjerg, José M.A. Moreira   +1 more
wiley   +1 more source

Correction: Graft rejection across solid organ transplants: mechanisms, monitoring, and immunosuppressive therapeutics. [PDF]

Front Surg
Danso EA, Oduoye MO, Enuh WC, Wamiq U, Shuja H, Sawaira F, Fatima H, Tameez-Ud-Din S.   +7 more
europepmc   +1 more source

Integrative omics in translational pharmacology: A target‐credibility framework for biomarker‐guided therapy

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
Integrative omics strengthens target credibility by combining causal, functional, pharmacological and tissue‐context evidence. Go, refine and stop decisions convert multi‐omics findings into actionable translational choices. Biomarker readiness requires analytical validity, clinical validity, utility and implementation within a defined context of use ...
Ruba Altahla, Zhaowei Wang, Shan‐Jie Rong, Chaoyi Li, Nasir Jadgal, Mohammad Javad Mehran, Mansoor Bolideei, Jamal Alshorman   +7 more
wiley   +1 more source

CYP2D6 Metabolizer Status and Mortality in Metoprolol Users. [PDF]

Clin Transl Sci
de Denus S, Oussaïd E, Meloche M, Bertrand AX, Leclair G, Cyr MC, Jutras M, Gaulin MJ, Mongrain I, Busseuil D, Tardif JC, Dubé MP.   +11 more
europepmc   +1 more source